Because immature blood vessels without pericytes’ support tend to be more vulnerable to anti-VEGF therapies (25), we performed double staining of CD31 and the pericyte marker NG2 and observed that mcr84 increased pericyte coverage of the remaining tumor vessels (Figure 1E), which is typically associated with improved vascular function (26). This evidence concerns the gene VEGFA and neoplasm.